These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

656 related items for PubMed ID: 19622901

  • 1. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
    Skarlos DV, Timotheadou E, Galani E, Samantas E, Grimani I, Lianos E, Aravantinos G, Xanthakis I, Pentheroudakis G, Pectasides D, Fountzilas G.
    Oncology; 2009; 77(2):107-12. PubMed ID: 19622901
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.
    Lyman GH, Lalla A, Barron RL, Dubois RW.
    Clin Ther; 2009 May; 31(5):1092-104. PubMed ID: 19539110
    [Abstract] [Full Text] [Related]

  • 4. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
    Schippinger W, Holub R, Dandachi N, Bauernhofer T, Samonigg H.
    Oncology; 2006 May; 70(4):290-3. PubMed ID: 16899982
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer.
    Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett J, Renwick JJ.
    Oncol Rep; 2003 May; 10(3):715-24. PubMed ID: 12684649
    [Abstract] [Full Text] [Related]

  • 10. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
    Heaney ML, Toy EL, Vekeman F, Laliberté F, Dority BL, Perlman D, Barghout V, Duh MS.
    Cancer; 2009 Oct 15; 115(20):4839-48. PubMed ID: 19637341
    [Abstract] [Full Text] [Related]

  • 11. Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG).
    Kahán Z, Spanik S, Wagnerova M, Skacel T, Planko B, Fitzthum E, Lindner E, Soldatenkova V, Zielinski CC, Brodowicz T.
    Breast Cancer Res Treat; 2008 Dec 15; 112(3):557-63. PubMed ID: 18189160
    [Abstract] [Full Text] [Related]

  • 12. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.
    Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L, Ershler WB.
    Oncologist; 2007 Dec 15; 12(12):1416-24. PubMed ID: 18165618
    [Abstract] [Full Text] [Related]

  • 13. Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer.
    Schuman SI, Lambrou N, Robson K, Glück S, Myriounis N, Pearson JM, Lucci JA.
    J Support Oncol; 2009 Dec 15; 7(6):225-8. PubMed ID: 20380330
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy.
    André N, Kababri ME, Bertrand P, Rome A, Coze C, Gentet JC, Bernard JL.
    Anticancer Drugs; 2007 Mar 15; 18(3):277-81. PubMed ID: 17264759
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
    Papaldo P, Lopez M, Marolla P, Cortesi E, Antimi M, Terzoli E, Vici P, Barone C, Ferretti G, Di Cosimo S, Carlini P, Nisticò C, Conti F, Di Lauro L, Botti C, Di Filippo F, Fabi A, Giannarelli D, Calabresi F.
    J Clin Oncol; 2005 Oct 01; 23(28):6908-18. PubMed ID: 16129844
    [Abstract] [Full Text] [Related]

  • 17. Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline-containing chemotherapy with pegfilgrastim support.
    Brugger W, Bacon P, Lawrinson S, Romieu G.
    Crit Rev Oncol Hematol; 2009 Dec 01; 72(3):265-9. PubMed ID: 19596586
    [Abstract] [Full Text] [Related]

  • 18. A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.
    Yamamoto N, Sekine I, Nakagawa K, Takada M, Fukuoka M, Tanigawara Y, Saijo N.
    Jpn J Clin Oncol; 2009 Jul 01; 39(7):425-30. PubMed ID: 19395467
    [Abstract] [Full Text] [Related]

  • 19. Different schedules of granulocyte growth factor support for patients with breast cancer receiving adjuvant dose-dense chemotherapy: a prospective nonrandomized study.
    Hendler D, Rizel S, Yerushalmi R, Neiman V, Bonilla L, Braunstein R, Sulkes A, Stemmer SM.
    Am J Clin Oncol; 2011 Dec 01; 34(6):619-24. PubMed ID: 21217400
    [Abstract] [Full Text] [Related]

  • 20. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
    Weycker D, Malin J, Barron R, Edelsberg J, Kartashov A, Oster G.
    Am J Clin Oncol; 2012 Jun 01; 35(3):267-74. PubMed ID: 21378538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.